JP5797755B2 - Ｐｏｈ誘導体を含む医薬組成物 - Google Patents

Ｐｏｈ誘導体を含む医薬組成物 Download PDF

Info

Publication number
JP5797755B2
JP5797755B2 JP2013527140A JP2013527140A JP5797755B2 JP 5797755 B2 JP5797755 B2 JP 5797755B2 JP 2013527140 A JP2013527140 A JP 2013527140A JP 2013527140 A JP2013527140 A JP 2013527140A JP 5797755 B2 JP5797755 B2 JP 5797755B2
Authority
JP
Japan
Prior art keywords
poh
cancer
tmz
cells
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013527140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505008A5 (enExample
JP2014505008A (ja
Inventor
チェン、トーマス
レヴィン、ダニエル
プパッリ、サティッシュ
Original Assignee
ネオンク テクノロジーズ インク．
ネオンク テクノロジーズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオンク テクノロジーズ インク．, ネオンク テクノロジーズ インク． filed Critical ネオンク テクノロジーズ インク．
Publication of JP2014505008A publication Critical patent/JP2014505008A/ja
Publication of JP2014505008A5 publication Critical patent/JP2014505008A5/ja
Application granted granted Critical
Publication of JP5797755B2 publication Critical patent/JP5797755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/05—Alcohols containing rings other than six-membered aromatic rings
    • C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
JP2013527140A 2010-08-27 2011-08-26 Ｐｏｈ誘導体を含む医薬組成物 Active JP5797755B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37774710P 2010-08-27 2010-08-27
US61/377,747 2010-08-27
US201161471402P 2011-04-04 2011-04-04
US61/471,402 2011-04-04
PCT/US2011/049392 WO2012027693A2 (en) 2010-08-27 2011-08-26 Pharmaceutical compositions comprising poh derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015006736A Division JP5982507B2 (ja) 2010-08-27 2015-01-16 Ｐｏｈ誘導体を含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2014505008A JP2014505008A (ja) 2014-02-27
JP2014505008A5 JP2014505008A5 (enExample) 2014-10-16
JP5797755B2 true JP5797755B2 (ja) 2015-10-21

Family

ID=45724091

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013527140A Active JP5797755B2 (ja) 2010-08-27 2011-08-26 Ｐｏｈ誘導体を含む医薬組成物
JP2015006736A Active JP5982507B2 (ja) 2010-08-27 2015-01-16 Ｐｏｈ誘導体を含む医薬組成物
JP2016151115A Active JP6431009B2 (ja) 2010-08-27 2016-08-01 Ｐｏｈ誘導体を含む医薬組成物
JP2018206892A Pending JP2019052154A (ja) 2010-08-27 2018-11-01 Ｐｏｈ誘導体を含む医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015006736A Active JP5982507B2 (ja) 2010-08-27 2015-01-16 Ｐｏｈ誘導体を含む医薬組成物
JP2016151115A Active JP6431009B2 (ja) 2010-08-27 2016-08-01 Ｐｏｈ誘導体を含む医薬組成物
JP2018206892A Pending JP2019052154A (ja) 2010-08-27 2018-11-01 Ｐｏｈ誘導体を含む医薬組成物

Country Status (8)

Country Link
US (12) US9499461B2 (enExample)
EP (5) EP3173080B1 (enExample)
JP (4) JP5797755B2 (enExample)
CN (3) CN103168018B (enExample)
BR (1) BR112013004698B1 (enExample)
DK (1) DK3685835T3 (enExample)
ES (4) ES3034958T3 (enExample)
WO (1) WO2012027693A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018035148A (ja) * 2011-11-21 2018-03-08 ネオンク テクノロジーズ インク． 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物
JP2019052154A (ja) * 2010-08-27 2019-04-04 ネオンク テクノロジーズ インク． Ｐｏｈ誘導体を含む医薬組成物
US12383621B2 (en) 2010-08-27 2025-08-12 University Of Southern California Pharmaceutical compositions comprising POH derivatives

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054333A1 (en) * 2013-10-08 2015-04-16 Neonc Technologies, Inc. Methods of treating cancer using compositions comprising perillyl alcohol derivative
US9913838B2 (en) * 2010-08-27 2018-03-13 Neonc Technologies, Inc. Methods of treating cancer using compositions comprising perillyl alcohol derivative
US11147809B2 (en) 2010-08-27 2021-10-19 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
WO2018005994A1 (en) * 2016-07-01 2018-01-04 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
BR112014006153A2 (pt) 2011-09-16 2020-12-01 Nanocare Technologies, Inc. composição farmacêutica, e, método para tratar um distúrbio
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
WO2016064959A1 (en) * 2014-10-21 2016-04-28 Odin Biotech Two-layer ocular implant comprising a tyrosine kinase inhibitor
TWI677342B (zh) * 2014-10-27 2019-11-21 美商尼翁客技術公司 紫蘇醇衍生物於製備用於治療鼻咽癌的醫藥組成物之用途
AU2015373915A1 (en) 2014-12-31 2017-08-10 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
CN107613768B (zh) * 2015-02-12 2020-10-20 NeOnc技术股份有限公司 包含紫苏醇衍生物的药物组合物
US10562901B2 (en) * 2016-09-22 2020-02-18 The University Of Massachusetts Temozolomide compounds, polymers prepared therefrom, and method of treating a disease
CN110267538B (zh) * 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
WO2018122724A1 (en) * 2016-12-27 2018-07-05 Granules India Limited Temozolomide process
US11559508B2 (en) 2017-04-19 2023-01-24 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives and methods of use
WO2019014420A1 (en) * 2017-07-12 2019-01-17 Azhc, Llc COMPOSITIONS AND METHODS FOR REDUCING MEDICATION ERRORS
JP2020531518A (ja) * 2017-08-24 2020-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー アルデヒドデヒドロゲナーゼ３ａ１のモノテルペン活性化剤およびその使用法
CN107789349A (zh) * 2017-12-01 2018-03-13 新乡医学院 治疗阿尔海默氏综合症的药物组合物及其应用
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法
US20210244820A1 (en) * 2018-06-15 2021-08-12 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives
CN112469401A (zh) * 2018-06-15 2021-03-09 尼昂克技术公司 包含poh衍生物的药物组合物
CN116615197A (zh) * 2020-11-12 2023-08-18 NeOnc技术股份有限公司 用紫苏醇治疗复发性胶质母细胞瘤
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架
EP4323070A4 (en) * 2021-04-16 2025-03-26 University Of Southern California PHARMACEUTICAL COMPOSITIONS CONTAINING POH DERIVATIVES
EP4329722A4 (en) * 2021-04-28 2025-03-26 University of Southern California USE OF PERILLYL ALCOHOL TO ENHANCE LEVO-DOPA RELEASE
TWI849808B (zh) * 2022-03-18 2024-07-21 共信醫藥科技股份有限公司 藥物組成物及化療劑用於製備治療癌症之藥物的用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508602A (en) 1974-04-01 1978-04-26 Bush Boake Allen Ltd Production of esters of perillyl alcohol
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
US4272441A (en) * 1980-03-13 1981-06-09 Fmc Corporation Preparation of carbamates
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US6313176B1 (en) 1989-10-17 2001-11-06 Everett J. Ellinwood, Jr. Dosing method of administering deprenyl via intraoral administration or inhalation administration
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US5587402A (en) 1992-04-09 1996-12-24 Wisconsin Alumni Research Foundation Regression of mammalian leukemia cell tumors
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19541963A1 (de) * 1995-11-10 1997-05-15 Henkel Kgaa Carbonylverbindungen
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6143227A (en) 1997-07-30 2000-11-07 Visteon Global Technologies, Inc. Method for injection molding an article having film covered flanges
US5994598A (en) 1998-01-15 1999-11-30 Doyle E. Chastain Method of preparing perillyl alcohol and perillyl acetate
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
HUP0101608A2 (hu) 1998-04-18 2002-03-28 Glaxo Group Limited Aeroszol formájú gyógyszerkészítmény és eljárás előállítására
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
US6133324A (en) 1998-05-07 2000-10-17 The Regents Of The University Of California Use of perillyl alcohol in organ transplantation
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
DK1169019T3 (da) 1999-04-14 2003-06-02 Glaxo Group Ltd Farmaceutisk aerosolformulering
JP5118792B2 (ja) 2000-01-14 2013-01-16 株式会社フコク ダンパおよびその製造方法
US20020010128A1 (en) 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US6378819B1 (en) 2000-08-21 2002-04-30 William W. Johnson Implement mounting assembly for attachment to a vehicle
US20050250854A1 (en) 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
US7816398B2 (en) 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
AU2002360547A1 (en) * 2001-12-11 2003-07-24 Dor Biopharma, Inc. Monoterpene compositions and uses thereof
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US6994083B2 (en) 2001-12-21 2006-02-07 Trudell Medical International Nebulizer apparatus and method
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
AU2003253890A1 (en) * 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
DE10308278B4 (de) * 2003-02-26 2007-07-05 Dr. André Rieks, Labor für Enzymtechnologie GmbH Antimikrobielle Wirkstoffe gegen Bakterien, Hefen und Schimmelpilze
US7015349B2 (en) * 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
JP4537956B2 (ja) 2003-03-26 2010-09-08 クリングルファーマ株式会社 喘息治療剤
CA2534729A1 (en) 2003-08-15 2005-02-24 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2570754A1 (en) 2004-06-23 2006-01-05 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of burns
EP1805311A2 (en) 2004-10-14 2007-07-11 Plant Research International B.V. Terpene hydroxylation
US7483173B2 (en) 2005-03-10 2009-01-27 Kabushiki Kaisha Toshiba Data processor having a synchronizing function of a plurality of chips
US7725813B2 (en) 2005-03-30 2010-05-25 Arizan Corporation Method for requesting and viewing a preview of a table attachment on a mobile communication device
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US20100112780A1 (en) 2005-07-12 2010-05-06 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Microwave-Induced Ion Cleaving and Patternless Transfer of Semiconductor Films
EP1928484B1 (en) 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
DE202006011065U1 (de) 2006-07-18 2006-11-02 Testo Ag Messanordnung zur Strömungsmessung in einem Kanal
CA2694166A1 (en) 2006-07-31 2008-02-07 Bio-Tree Systems, Inc. Blood vessel imaging and uses therefor
US20100168228A1 (en) 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
CA2679670A1 (en) * 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Indole and benzothiophene compounds as modulators of the histamine h3 receptor
ES2732230T3 (es) 2007-04-11 2019-12-12 Canbas Co Ltd Compuestos que anulan el punto de control G2 del ciclo celular para una utilización en el tratamiento del cáncer
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
EP2042167A1 (en) 2007-09-26 2009-04-01 Aisa Therapeutics Use of a monoterpene to induce tissue repair
US7745670B2 (en) 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
JP5622720B2 (ja) 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
US8058469B2 (en) 2008-11-03 2011-11-15 Sabic Innovative Plastics Ip B.V. Method for making carbamates, ureas and isocyanates
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
US9651554B2 (en) 2010-09-24 2017-05-16 The Methodist Hospital Research Institute Molecular diagnostic methods for predicting brain metastasis of breast cancer
CN107613768B (zh) 2015-02-12 2020-10-20 NeOnc技术股份有限公司 包含紫苏醇衍生物的药物组合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019052154A (ja) * 2010-08-27 2019-04-04 ネオンク テクノロジーズ インク． Ｐｏｈ誘導体を含む医薬組成物
US12383621B2 (en) 2010-08-27 2025-08-12 University Of Southern California Pharmaceutical compositions comprising POH derivatives
JP2018035148A (ja) * 2011-11-21 2018-03-08 ネオンク テクノロジーズ インク． 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物

Also Published As

Publication number Publication date
US9663428B2 (en) 2017-05-30
US9499461B2 (en) 2016-11-22
EP2883543B1 (en) 2016-11-16
JP2017031150A (ja) 2017-02-09
ES2610425T3 (es) 2017-04-27
EP2898883A1 (en) 2015-07-29
US20140364471A1 (en) 2014-12-11
US20190275031A1 (en) 2019-09-12
EP2609064A4 (en) 2014-04-23
EP2609064B1 (en) 2016-09-28
CN103168018A (zh) 2013-06-19
JP2019052154A (ja) 2019-04-04
US20200078355A1 (en) 2020-03-12
WO2012027693A2 (en) 2012-03-01
US20160039731A1 (en) 2016-02-11
CN105078973B (zh) 2020-10-09
CN110464718A (zh) 2019-11-19
ES2600928T3 (es) 2017-02-13
US20130210877A1 (en) 2013-08-15
CN103168018B (zh) 2015-10-21
US10092562B2 (en) 2018-10-09
BR112013004698A2 (pt) 2016-05-10
EP3685835B1 (en) 2025-04-09
DK3685835T3 (da) 2025-07-21
US20170369408A1 (en) 2017-12-28
BR112013004698B1 (pt) 2022-03-22
JP6431009B2 (ja) 2018-11-28
EP3685835A1 (en) 2020-07-29
WO2012027693A3 (en) 2012-05-10
JP2014505008A (ja) 2014-02-27
ES2610810T3 (es) 2017-05-03
EP3173080A1 (en) 2017-05-31
US20140364472A1 (en) 2014-12-11
EP2898883B1 (en) 2016-11-23
US20220133712A1 (en) 2022-05-05
EP3173080B1 (en) 2019-12-11
EP2609064A2 (en) 2013-07-03
US20130203828A1 (en) 2013-08-08
US8916545B2 (en) 2014-12-23
US9580372B2 (en) 2017-02-28
US20170128578A1 (en) 2017-05-11
ES3034958T3 (en) 2025-08-27
JP2015110612A (ja) 2015-06-18
US20210283127A1 (en) 2021-09-16
US11077104B2 (en) 2021-08-03
US20170119758A1 (en) 2017-05-04
JP5982507B2 (ja) 2016-08-31
EP2883543A1 (en) 2015-06-17
CN105078973A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
JP6431009B2 (ja) Ｐｏｈ誘導体を含む医薬組成物
JP6674957B2 (ja) ペリリルアルコール誘導体を含む医薬組成物
JP6122564B2 (ja) イソペリリルアルコールの使用方法および装置
JP2018035148A (ja) 重水素強化ペリリルアルコール、イソペリリルアルコール、及びその誘導体を含む医薬組成物
US20210244820A1 (en) Pharmaceutical compositions comprising poh derivatives
CN112469401A (zh) 包含poh衍生物的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140826

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140826

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150819

R150 Certificate of patent or registration of utility model

Ref document number: 5797755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250